^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GC101 TIL
i
Other names: GC101 TIL, autologous tumor infiltrating lymphocytes, tumor infiltrating lymphocytes
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gencells Therapeutics
Drug class:
Immunostimulant
Related drugs:
18d
A Phase II Study of GC101 in NSCLC (clinicaltrials.gov)
P2, N=28, Not yet recruiting, Shanghai Juncell Therapeutics
New P2 trial
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • MET exon 14 mutation • RET mutation • MET mutation • KRAS G12 • EGFR negative • NTRK fusion
|
GC101 TIL
4ms
A Study of TIL in Advanced Solid Tumors (CZ) (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Shanghai Juncell Therapeutics | Initiation date: Dec 2025 --> May 2026
Trial initiation date
|
cyclophosphamide • GC101 TIL
5ms
A Study of TIL in Advanced Solid Tumors (CZ) (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Shanghai Juncell Therapeutics
New P1 trial
|
cyclophosphamide • GC101 TIL
5ms
Study of GC101 TIL in Brain Glioma (Soochow2) (clinicaltrials.gov)
P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
cyclophosphamide • GC101 TIL
5ms
MIZAR-002: A Phase 1b Study of GC101 TIL in Advanced Melanoma (clinicaltrials.gov)
P1/2, N=18, Completed, Shanghai Juncell Therapeutics | Recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2025
Trial completion • Trial completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
GC101 TIL
5ms
A Study of GC101 TIL in Advanced Breast Cancer (10hospital) (clinicaltrials.gov)
P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Dec 2024 --> Dec 2026 | Trial completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date
|
cyclophosphamide • GC101 TIL
5ms
MIZAR: A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=43, Completed, Shanghai Juncell Therapeutics | Recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025 | Trial primary completion date: Nov 2025 --> Apr 2025
Trial completion • Trial completion date • Trial primary completion date
|
Tyvyt (sintilimab) • GC101 TIL
over1year
MIZAR-005: A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Jan 2025 --> Jan 2026
Trial primary completion date
|
GC101 TIL
over1year
MIZAR: A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, Shanghai Juncell Therapeutics | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
Trial completion date • Trial primary completion date
|
Tyvyt (sintilimab) • GC101 TIL
over1year
MIZAR-003: A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma (clinicaltrials.gov)
P2, N=98, Recruiting, Shanghai Juncell Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
cisplatin • carboplatin • paclitaxel • Tyvyt (sintilimab) • temozolomide • dacarbazine • GC101 TIL
over1year
MIZAR-003: Study Evaluating GC101 TIL (Autologous TIL) in the Treatment of Patients With Advanced Melanoma (clinicaltrials.gov)
P2, N=98, Not yet recruiting, Shanghai Juncell Therapeutics
New P2 trial • Metastases
|
carboplatin • paclitaxel • Tyvyt (sintilimab) • temozolomide • GC101 TIL
over1year
MIZAR-005: A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Juncell Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
GC101 TIL
Share via
